A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
Latest Information Update: 13 Jun 2023
Price :
$35 *
At a glance
- Drugs AAV RS1 (Primary)
- Indications Retinoschisis
- Focus Adverse reactions
- Sponsors Applied Genetic Technologies Corporation
- 08 Jun 2023 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 09 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.